AIDS dementia: Synthesis and properties of a derivative of 3′-azido-3′-deoxythymidine (AZT) that may become ‘locked’ in the central nervous system  by Torrence, Paul F. et al.
Volume 234, number 1, 135-140 FEB 06006 July 1988 
AIDS dementia: synthesis and properties of a derivative of 
3’-azido-3’-deoxythymidine (AZT) that may become ‘locked’ in the 
central nervous system 
Paul F. Torrence, Jun-ei Kinjo, Krystyna Lesiak, Jan Balzarini* and Erik De Clercq* 
Section on Biomedical Chemistry, Laboratory of Analytical Chemistry, National Institute of Diabetes and Digestive and 
Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA and *Rega Institute, Catholic University of 
Leuven. Minderbroedersstraat IO, B-3000 Leuven, Belgium 
Received 3 May 1988 
In an attempt to provide a derivative of 3’-azido-3’-deoxythymidine (AZT) which might be sequestered in the central 
nervous system and release AZT, the dihydropyridine ester 5’-(1,4-dihydro-l-methyl-3-pyridinylcarbonyl)-3’-deoxythy- 
midine, was synthesized in a three step sequence. This material showed potent anti-HIV-l activity in MT-4 cells most 
probably by hydrolysis to the parent nucleoside, AZT. This dihydropyridine derivative of AZT could be easily oxidized 
to a positively charged pyridinium derivative of AZT in rat brain cytosol. In turn the pyridinium form could be hydro- 
lyzed, non-enzymatically, to AZT. 
HIV-l; Antiviral activity; Anti-retrovirus agent; Nucleoside; (Rat brain) 
1. INTRODUCTION 
While it has been recognized for some time that 
profound immune dysfunction is a hallmark of in- 
fection with human immunodeficiency virus type 1 
(HIV-l), it is now also clear that serious neurologic 
dysfunction, the AIDS dementia complex, is an 
important cause of morbidity in many patients 
[ 1,2]. While it is presently not certain whether or 
not the pathology of AIDS dementia complex may 
be caused by a direct infection of the brain by 
HIV-l or by an indirect mechanism (e.g. in- 
terference with neuroleukin [3-51) [1,2], it is cer- 
tain that brain macrophages, microglia as well as 
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multinucleated cells can be productively infected 
with HIV-l [6-lo], and that the proviral DNA, 
viral nucleic acid, viral antigens, as well as HIV-l 
virons are present in the brains of patients with 
AIDS dementia [2]. This invasion of the nervous 
system by HIV-l, coupled with the possibility that 
it could create a reservoir of persistent infection 
even if peripheral clearance were realized [l 11, has 
led to the general agreement that an ideal 
chemotherapeutic agent for HIV-l should 
penetrate and be highly active in the CNS [12]. 
3 ’ -Azido-3 ’ -deoxythymidine [ 131 (AZT, zido- 
vudine, Retrovir) is a nucleoside analog that in- 
hibits HIV replication in vitro [14] and can 
decrease mortality and the frequency of oppor- 
tunistic infections in selected patients with AIDS 
and AIDS-related complex [ 14-161. It also leads to 
a marked improvement in neurological manifesta- 
tions of AIDS dementia [1,17]. While most 
nucleosides as polar molecules do not readily cross 
the blood-brain barrier, AZT has been found in 
cerebrospinal fluid of patients on AZT therapy 
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[ 15,181. Some uncertainty regarding specific brain 
levels of AZT exists, since CSF levels may reflect 
transport through the choroid plexus. For in- 
stance, radioactive AZT was not significantly 
transported into the brain of rats [19]. On the 
other hand, AZT stands apart as a nucleoside 
analog in that it appears to cross the cell membrane 
mainly by nonfacilitated diffusion and not by 
means of a nucleoside transport system [20]. 
Regardless of the efficiency with which AZT 
crosses the blood-brain barrier, it is to be expected 
that it may leave the CNS by the same mechanism 
with equal facility. In view of the possibility that 
HIV-l may replicate in the brain [1,2], it may be 
of interest o investigate the properties of an agent 
which might accumulate in the brain, thereby pro- 
viding a sustained release of the antiviral to main- 
tain a therapeutically effective concentration. 
Bodor and colleagues have achieved brain- 
specific delivery of dopamine, phenylethylamine, 
N-pyridinium-2-carbaldoxime chloride, testoster- 
one, estradiol, tryptamine and other pharma- 
cological agents by means of a redox delivery 
system based on the chemistry of a dihydro- 
pyridine-pyridinium salt interconversion [21-241. 
The basic concept is the generation of an adduct of 
the pertinent drug to a 1,Cdihydropyridine which 
is a neutral lipophilic molecule and may cross the 
blood-brain barrier [21,22]. In the brain, redox 
systems, such as dehydrogenases, may convert the 
dihydropyridine to a pyridinium form which, as a 
positively charged molecule, cannot readily exit the 
blood-brain barrier. This adduct may then be 
cleaved to yield the active drug. In this report, we 
describe the application of this principle to AZT 
and the resultant properties of such an adduct. 
2. MATERIALS AND METHODS 
AZT was purchased from Sigma (St. Louis, MO) or syn- 
thesized according to Horwitz et al. [25] and nicotinyl chloride 
was from Lancaster Synthesis (Windham, NH). HPLC was 
with ap-Bondapak Crs column (3.9 x 300 mm) with a mobile 
phase of CH3CN/O.O1 M NazHPOA (1: 1) with 0.001 M n- 
octane sulfonic acid at a flow rate of 1 ml/min. Detection was 
at 254 nm. Under these conditions, retention times were as 
follows: AZT, 4.0 min; compound 4, 5.3 min; compound 3, 
12.5 min; nicotinic acid methiodide, 3.9 min. Infrared spectra 
were determined on a Beckman 4230 instrument, ultraviolet 
spectra on a Beckman DU8B spectrophotometer, NMR 
(300 MHz) on a Varian XL300 spectrometer, and mass spectra 
on either a Finnigan/Extrel 1015 (chemical ionization) or on a 
136 
Finnigan thermospray (TSP46) instrument (positive ion ther- 
mospray). 
Rat brain SIO was prepared by homogenization of brain tissue 
in 50 mM Tris buffer (pH 7.4) followed by centrifugation at 
10000 x g for 10 min. The supernatant was used immediately 
for the assays. 
2.1. AZT nicotinate /5 ‘-(3-pyridinylcarbonyi)-3 ‘-azido-3 I- 
deoxythymidine (2)/ 
3’-Azido-3’-deoxythymidine (AZT, dried over PzOS, 3.1 g, 
11.6 mmol) was dissolved in dry pyridine (20 ml). Then the 
pyridine was removed in vacua. This was repeated three times 
to remove all traces of moisture. Finally, the AZT was taken up 
in anhydrous pyridine, and nicotinyl chloride (2.34 g, 13 mmol) 
was added. The mixture was maintained at 70°C for 1.5 h. TIC 
CHCl3IMeOH (9: 1) showed a small quantity of unreacted 
AZT, so an additional amount of nicotinyl chloride (180 mg) 
was added. After a further 0.5 h at 7O”C, no AZT remained. 
The reaction mixture was cooled and pyridine was removed in 
vacua. Xylene was added and evaporated to aid in the removal 
of residual pyridine. The reaction mixture then was applied to 
a column of silica gel (100 g) and it was eluted with 
CHCls/MeOH (50: 1). Appropriate fractions were combined to 
give, after evaporation, AZT nicotinate (2, 4.1 g, 95%). 
Trituration with cyclohexane produced a foamy powder. 
Recrystallization from acetone/hexane gave 2 as colorless 
needles: m.p. 136-137°C; UVI,,, (CHsOH) 263 nm (E 12800), 
214 nm (6 19100); IR (KBr) 2100 cm-’ (Nj), 1730 cm-’ (ester 
C=O); Cl-MS, m/z 373 (M + H); NMR (CDCl3) 6: 1.78 
(s,3,5-CH3); 2.54 (t*, 2, J = 7 Hz, 2’-H’s), 4.18 (br dt, 1, J = 
7 Hz, 4 Hz, 4’H). 4.43 (q*, 1, J = 7 Hz, 3’H), 4.61 and 4.69 
(dd, each 1, J = 12 Hz, 4 Hz, ~‘H’s), 6.08 (t, 1, J = 7 Hz, 
l’H), 7.15 (d, 1, J= 1 Hz, 6H), 7.45 (dd, 1, J = 8 Hz, 5 Hz, 
pyridine 5H), 8.34 (dt, 1, J = 8 Hz, 2 Hz, pyridine 4H), 8.86 
(br d, 1, J = 4 Hz, pyridine 6H), 9.30 (br s, 1, pyridine 2H). 
Anal. Calc. for Ct_sHte,N605: C, 51.61; H, 4.33; N, 22.57. 
Found: C, 51.69; H, 4.38; N, 22.52. 
2.2. AZT nitotinate methiodide [5 ‘-(I-methyl-3-pyridinium- 
carbonyl)-3 ‘-azido-3 ‘-deoxythymidine(3)j 
AZT nicotinate (2, 1.35 g, 2.6 mmol) was dissolved in 
acetone (30 ml). lodomethane (1.5 ml, 24 mmol) then was add- 
ed to this solution and the reaction mixture was refluxed for 
5 h. The reaction mixture was cooled and the yellow precipitate 
that formed was removed by filtration and dried in vacua to 
give 1.85 g (3.6 mmol, yield 100%) of a yellow amorphous 
powder: UV A,,, (CHIOH) 264 nm (e 13100), 217 nm (t 
28000); IR(KBr) 2110 cm-’ (NJ), 1740 cm-’ (ester C=O); 
NMR (DzO) 6: 1.80 (s, 3, 5-CHs); 2.6-2.7 (m, 2, 2’H’s); 4.34 
(m, 1, 4’H), 4.51 (s, 3, NCHs), 4.58 (q*, 1, J = 7 Hz, 3’H), 
4.7-4.9(m.2, ~‘H’s), 6.19(dd, l,J= 7 Hz, 5 Hz, l’H), 7.50 
(s, 1, 6H), 8.24 (t*, 1, J = 7 Hz, pyridine 5H), 9.06 (br d, 2, 
J = 7 Hz, pyridine 4 and 6 H), 9.49 (s, 1, pyridine 2H). 
Anal. talc. for CrrHt9N60sl: C, 39.70; H, 3.72; N, 16.34; 1, 
24.68. Found: C, 39.86; H, 3.86; N, 16.19; I, 24.51. 
* This represents an apparent multiplicity resulting from either 
fortuitous nearly equivalent .I values or J values approaching 
zero. 
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2.3. HPAZT [5 ‘-(1,4-dihydro-I-melhyt-3-pyridinylcarbonylk 
3 ‘-azido-3 ‘-deoxythymidine(4)) 
The pyridinium salt (3, 100 mg, 0.2 mmol), sodium 
dithionite (Na&04, 174 mg, 1 mmol) and sodium bicarbonate 
(84 mg, 1 mmol) were combined as solids and stirred in a flask 
in an ice-bath. Cold deaerated water (10 ml) was added to the 
mixture. Then the ice-bath was removed and the reaction mix- 
ture was stirred for 20 min at ambient temperature and then 
filtered. The precipitate was dried in vacua. The yield was 
50 mg (0.13 mmol, 65%) of a pale yellow amorphous powder; 
UV Amax (CH30H) 360 nm (6 7520), 265 nm (6 13200), 210 nm 
(6 25600); IR (KBr) 2110 cm-’ (NJ); m/z = 389 (M + H); NMR 
(CDCIj) 6: 1.93 (s, 3, S-CH3). 2.23 (dt, 1, J = 14.7 Hz, 2’-H.,), 
2.49 (m, 1, J = 14 Hz, 7 Hz, 2’He,), 2.94 (s, 3, N-CH3), 3.10 
(br s, 2, pyridine 4H), 4.13 (q*, 1, J = 4 Hz, 3 ‘H), 4.22 (dt, 1, 
J = 7 Hz, 4 Hz, 4’H), 4.37, 4.40 (dd, 1 each, J = 12, 4 Hz, 
both 5’H), 4.79 (dt, 1, J = 8 Hz, 4 Hz, pyridine 5H), 5.64 (dd, 
I, J = 8 Hz, 2 Hz, pyridine 6H), 6.16 (t’, I, J = 7 Hz, 1 ‘H), 
7.02 (s, 1, pyridine 2H, 7.25 (s, 1, 6H), 8.83 (br s, 1, 3 NH). 
Anal. talc. for Cr7H~cNe.0~ 1/2HzO: C, 51.38; H, 5.33; N, 
21.15; Found: C, 51.36; H, 5.29; N, 20.98. 
2.3. I. Cells 
Human lymphocyte MT-4 cells were kindly provided by Dr 
N. Yamamoto (Yamaguchi University, Yamaguchi, Japan). 
MT-4 cells were cultivated in RPM1 1640 medium (Gibco) and 
2 mM Hepes buffer, 10% (v/v) inactivated fetal calf serum 
(FCS) (Gibco) and 2 mM L-glutamine (Flow Laboratories). 
Murine C3H embryo fibroblasts were cultured in Eagle’s 
minimum essential medium (Gibco) containing 10% (v/v) inac- 
tivated FCS and 2 mM L-glutamine. 
2.3.2. Viruses 
HTLV-IIIa (designated HIV) stock was derived from a pool 
of American patients with AIDS and obtained from the super- 
natant of HIV-infected H9 cell cultures [26]. 
Moloney murine sarcoma virus (MSV) stock was prepared 
from tumors induced upon intramuscular inoculation of 
IO-day-old NMRI mice with MSV, as described in [27]. 
2.3.3. Anti-HIV assays 
MT-4 cells (5 x IO5 cells/ml) were suspended in fresh culture 
medium and infected with 200 CCIDso (cell culture infective 
dose - 50) HIV per ml cell suspension. Then IOOJ of the in- 
fected cell suspension was added to lOOpI of an appropriate 
dilution of test compound in 200~1 microplate wells (i.e. 20 
CCIDso HIV/200~1 well/5 x lo4 cells), and further incubated 
at 37°C. After incubation for 5 days, viable cell counts were 
determined for both virus-infected cell cultures and non- 
infected cell cultures. The 50% effective dose (EDSO) and 50% 
cytotoxic dose (CD~O) were defined as the compound concentra- 
tions which caused a 50% reduction in the number of viable 
cells (as compared to the untreated uninfected cell cultures) in 
the virus-infected and non-infected cell cultures, respectively. 
2.3.4. Transformation of C3H mouse embryo fibroblasts by 
Maloney murine sarcoma virus (MSV) 
C3H cells were seeded at 20000 cells per ml into wells of 
Costar Tissue Culture Cluster plates (48 welts per plate). 24 h 
later, cell cultures were infected with 80 foci-forming units of 
MSV for 90 min. whereupon the culture medium was replaced 
by 1 ml fresh medium containing different concentrations of 
the test compounds. After 6 days, transformation of the cells 
was examined microscopically. 
2.4. Chemical oxidation studies 
2.4.1. Oxidation by Hz02 
HPAZT (4, 5 mg) was dissolved in CHlCN (1 ml) and this 
solution was added to Hz02 (3%, 2 ml). The reaction mixture 
was maintained at 40°C and aliquots were removed at various 
times for HPLC analysis. At 30 min, partial oxidation to com- 
pound 3 had occurred together with hydrolysis to N- 
methylnicotinic acid and AZT. After 3 h, HPAZT had disap- 
peared from the reaction mixture. After 24 h, all of compound 
3 was converted to N-methylnicotinic acid and AZT. When 
compound 3 was added to 3% Hz02 solution at 4O”C, 
hydrolysis at AZ? was 30% complete in 1 h. 
2.4.2. Oxidation by AgN03 
HPAZT (4, 5 mg) was dissolved in saturated 
AgNOJCH3OH (1 ml). The reaction mixture was stirred for 
15 min at room temperature and then filtered. Anaiysis by 
HPLC showed quantitative conversion to compound 3 with no 
evidence of hydrolysis. 
2.4.3. Stability of HPAZT(4) 
Two separate solutions of HPAZT (4) (1 mg/ml in 10% 
DMSO) were prepared. One was kept at 37°C overnight while 
the other was stored at -20°C. The latter was unchanged, 
however, the solution kept at 37°C resulted in oxidation and 
conversion to an unidentified product (retention time 4.2 min). 
3. RESULTS AND DISCUSSION 
3.1. Chemistry 
The target compound (HPAZT, 4; fig.1) was 
synthesized according to the general approach suc- 
cessfully employed previously by Bodor and co- 
workers [21,22]. AZT (1) was acylated at the 
5 ’ -hydroxyl with nicotinyl chloride in pyridine to 
give the ester, 2, in nearly quantitative yield. 
Quaternization of compound 2 with methyl iodide 
provided a quantitative yield of the trigonellinate 
ester (3). Reduction of 3 was accomplished with 
basic sodium dithionite which routinely reduces 
substituted pyridinium salts to 1,4-dihydropyri- 
dines [25]. Under these conditions the azido group 
was not affected. HPAZT (4) was obtained in 65 % 
yield. The product, HPAZT, showed the bands in 
its ultraviolet spectrum typical for a similarly 
substituted 1,Cdihydropyridine [21-24,281. In the 
NMR spectrum, the dihydropyridine N-CH3 group 
underwent a 1.57 ppm upfield shift relative to the 
N-CH3 group of 3. The remainder of the NMR 
spectrum, including the appearance at 3.1 ppm of 
the two dihydropyridine C-4 hydrogens, cor- 
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Fig. 1. Synthetic scheme for the preparation of 5’ -( 1,4-dihydro-- 
1 -methyl-3-pyridinylcarbonyl)-3 ’ -azido-3 ‘-deoxythymidine 
(HPAZT, 4). 
roborated the 1,4_dihydropyridine structure. 
HPAZT (4) was reasonably stable considering 
its dihydropyridine nature. It was unchanged when 
stored overnight at - 20°C in an aqueous DMSO 
solution; however, maintenance of such a solution 
overnight at 37°C led to extensive decomposition. 
Under proper conditions, HPAZT (4) was readily 
oxidized back to the pyridinium form. Methanolic 
silver nitrate gave 3 (with nitrate rather than iodide 
as anion) in quantitative yield. Hydrogen peroxide 
also could oxidize 3, but in this case some 
hydrolysis of the ester linkage also took place. 
3.2. Anti-retrovirus effect 
3 ’ -Azido-3 ’ -dideoxythymidine (AZT, 1) and its 
esterified counterparts 2, 3 and 4 were evaluated 
for their inhibitory effects on the transformation 
of mouse embryo C3H fibroblast cells by Moloney 
murine sarcoma virus (MSV) (table 1). With an 
EDso of O.O34pM, AZT was the most potent in- 
hibitor, whereas PAZT (3, EDso 0.07 PM), 
HPAZT (4, EDso 0.159 PM) and 2 (ED50 0.24 ,LLM) 
showed a 2-, 5- and 7-fold higher ED~o, respective- 
ly. None of the compounds showed any cellular 
toxicity at 10pM as recorded microscopically. 
When examined for their inhibitory effect on the 
HIV-induced cytopathogenicity in MT-4 cells, 
AZT again proved the most powerful inhibitor of 
HIV replication (ED~o: 0.007 PM), followed by 
HPAZT (4), PAZT (3) and 2 (table 2). Their 50% 
Table 1 
Inhibitory effects of 5 ‘-substituted 3 ‘-azido-3 ‘-deoxythymi- 
dine derivatives on MSV-induced transformation of murine 
embryo C3H fibroblasts 
Compound EDso” kM) 
AZT (1) 0.034 
2 0.214 
PAZT (3) 0.070 
HPAZT (4) 0.159 
a 50% antiviral effective dose 
MCDb (LLM) 
110 
> 10 
> 10 
> 10 
b Minimum cytotoxic dose or dose required to cause a 
microscopically detectable alteration of normal cell 
morphology 
cytotoxic doses (CDY,) were 12,28, 47, and 99 ,LLM, 
respectively. 
Consequently, the selectivity index of AZT was 
about 1700, and that of 2, PAZT (3) and HPAZT 
(4) 2700, 3600, and 2800, respectively. 
Thus, in both the human and murine retrovirus 
system, the AZT derivatives exhibited an anti- 
retrovirus potency and selectivity that were similar 
to those of AZT. Therefore, one may assume that 
the AZT derivatives behave as prodrugs of AZT, 
and thus release the free nucleoside derivatives in 
the extra- or intracellular environment during in- 
cubation of the derivatives with the cells. 
Since phosphorylation of AZT by thymidine 
(dThd) kinase is a prerequisite for its anti- 
retrovirus activity 129,301, the addition of high 
concentrations of dThd should prevent the activity 
of the AZT derivatives if their activity is, as 
presumed, due to the release of AZT. Indeed, ad- 
dition of 250 ,uM dThd (in the presence of 500 ,LLM 
2’-deoxycytidine to avoid cytotoxicity of dThd) 
resulted in a decrease of the anti-HIV activity of 
AZT by more than 3 orders of magnitude, and, 
likewise, the anti-HIV activity of the AZT 
derivatives was decreased to the same extent (not 
shown). Furthermore, the cytotoxicity of all com- 
pounds for MT-4 cells was completely annihilated 
(CD50 > 400 PM) following addition of dThd (not 
shown). Thus, from the reversing effects of dThd 
on both the anti-HIV activity and cytotoxicity of 
the AZT derivatives one may infer that the latter 
act via the intermediary release of AZT. 
3.3. Biochemistry and pharmacology 
To address the question of whether or not 
HPAZT (4) could undergo the requisite series of 
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Table 2 
Inhibitory effect of 5 ‘-substituted 3 ’-azido-3 ’ -deoxythymidine 
derivatives on HIV-induced cytopathogenicity in MT-4 cells 
Compound EDxoa &M) 
AZT (1) 0.007 
2 0.037 
PAZT (3) 0.013 
HPAZT (4) 0.010 
a 50% antiviral effective dose 
b 50% cytotoxic dose 
CDsob @M) 
12 
99 
47 
28 
reactions necessary to fulfill its potential as a pro- 
drug form which may be transported into the cen- 
tral nervous system and oxidized to the positively 
charged pyridinium form, the metabolic fate of 
HPAZT (4) was examined in vitro in cytoplasmic 
extracts of rat brain. Incubation of HPAZT at 
37°C in a Tris buffer with 10000 x g supernatant 
from rat brain homogenate revealed that over a 
period of 2 h, HPAZT was converted gradually to 
the pyridinium form, PAZT (3) (fig.2). In con- 
junction with the disappearance of HPAZT from 
the incubation mixture, the concentration of 
PAZT (3) increased to an apparent steady state 
level and then began to decrease. Finally, after a 
lag phase the concentration of AZT (1) itself in- 
creased. These results demonstrate clearly that 
HPAZT can be converted readily to the 
pyridinium form PAZT by the enzymes present in 
rat brain. 
The AZT that forms during the course of the in- 
cubation of fig.2 most probably arises nearly ex- 
clusively from the newly formed PAZT (3) itself 
rather than HPAZT (4). The neutral ester linkage 
of the nicotinic acid esters seems relatively resistant 
to premature hydrolysis. The simple nicotinate 
ester (2) was quite stable during the course of a 2-h 
incubation under conditions identical to that of 
fig.2 (not shown). In Tris buffer or in rat blood, 
HPAZT (4) itself also was stable during incubation 
at 37°C. Conversely, PAZT (3) underwent a rapid 
hydrolysis to AZT (1) upon incubation with brain 
extract as in fig.2 or in Tris buffer. The half-life of 
PAZT under such conditions was approx. 40 min. 
Preliminary in vivo experiments have been car- 
ried out to determine if the above conversion of 
HPAZT to PAZT might occur in an intact animal. 
Male Sprague-Dawley rats were injected in- 
. - HPAZT 
A-PAZT 
. -ATT 
15 30 60 120 
TIME IMIN) 
Fig.2. Metabolism of HPAZT (4) in rat brain cytosol. HPAZT 
was incubated at a final concentration of 2 x 10m4 M at 37°C 
in a reaction mixture final volume of 500~1 of a 1 x 10-j M 
solution of HPAZT in 10% DMSO 50 mM bis, pH 7.4. At 
various time intervals ahquots were removed and diluted 
directly into 5 vols of ice-cold acetonitrile. These samples were 
kept at -20°C until the conclusion of the reaction at which 
point all samples were centrifuged for 10 min at 10000 x g and 
the supernatant carefully removed. Analysis was by injection of 
a 2Opl aliquot into the HPLC column and elution was as 
described in the experimental section. In the absence of brain 
extract, no pyridinium salt was formed nor was any hydrolysis 
of HPAZT detected under the same incubation conditions. 
travenously (tail vein) with HPAZT (20 mg/kg) in 
0.1-0.2 ml of DMSO. 1 h after injection, the 
animals were killed, the brains homogenized with 
acetonitrile/water (3 : 1) and, after centrifugation, 
the supernatants were analyzed by HPLC using the 
same system as employed for the experiments of 
fig.2. Under such conditions PAZT (3) was 
detected readily in the brain at levels of l-3 @g/g 
brain. Thus far no experiments have been con- 
ducted to attempt to optimize these levels. 
In summary, an efficient synthesis of a prodrug 
form of AZT has been described. This 
dihydropyridine derivative (HPAZT, 4) shows a 
high antiviral activity against HIV in MT-4 cells as 
well as prevention of transformation of mouse em- 
bryo fibroblasts by Moloney murine sarcoma 
virus. This activity is prevented by thymidine and 
most probably is mediated by hydrolysis to AZT. 
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HPAZT (4) is readily converted to the quaternary 
pyridinium salt PAZT (3) in rat brain cytosol. In 
turn PAZT (3) is readily hydrolyzed by a non- 
enzymatic pathway to AZT. Preliminary ex- 
periments have shown that upon injection of 
HPAZT in the periphery of the rat, the pyridinium 
salt (3) can be isolated from the brain. These 
results suggest that HPAZT (4) should be in- 
vestigated further as a means of delivering AZT to 
the central nervous system to inhibit HIV 
replication. 
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